Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.
2.

The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers-In Vitro Studies.

Gurbi B, Brauswetter D, Varga A, Gyulavári P, Pénzes K, Murányi J, Zámbó V, Birtalan E, Krenács T, Becker DL, Csala M, Vályi-Nagy I, Peták I, Dános K.

Cancers (Basel). 2019 Nov 22;11(12). pii: E1848. doi: 10.3390/cancers11121848.

3.

Novel Crizotinib-GnRH Conjugates Revealed the Significance of Lysosomal Trapping in GnRH-Based Drug Delivery Systems.

Murányi J, Varga A, Gyulavári P, Pénzes K, Németh CE, Csala M, Pethő L, Csámpai A, Halmos G, Peták I, Vályi-Nagy I.

Int J Mol Sci. 2019 Nov 8;20(22). pii: E5590. doi: 10.3390/ijms20225590.

4.

Targeted drug combination therapy design based on driver genes.

Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, Kéri G, Peták I, Vályi-Nagy I.

Oncotarget. 2019 Sep 3;10(51):5255-5266. doi: 10.18632/oncotarget.26985. eCollection 2019 Sep 3.

5.

Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.

Brauswetter D, Gurbi B, Varga A, Várkondi E, Schwab R, Bánhegyi G, Fábián O, Kéri G, Vályi-Nagy I, Peták I.

PLoS One. 2017 Sep 28;12(9):e0185687. doi: 10.1371/journal.pone.0185687. eCollection 2017.

6.

Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion.

Kocsis J, Árokszállási A, András C, Balogh I, Béres E, Déri J, Peták I, Jánváry L, Horváth Z.

J Gastrointest Oncol. 2017 Apr;8(2):E32-E38. doi: 10.21037/jgo.2017.01.06.

7.

p16INK4 expression is of prognostic and predictive value in oropharyngeal cancers independent of human papillomavirus status: a Hungarian study.

Brauswetter D, Birtalan E, Danos K, Kocsis A, Krenacs T, Timar J, Mihalyi R, Horcsik D, Polony G, Tamas L, Petak I.

Eur Arch Otorhinolaryngol. 2017 Apr;274(4):1959-1965. doi: 10.1007/s00405-016-4412-8. Epub 2016 Dec 20.

PMID:
27999998
8.

Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.

Brauswetter D, Dános K, Gurbi B, Félegyházi ÉF, Birtalan E, Meggyesházi N, Krenács T, Tamás L, Peták I.

Virchows Arch. 2016 May;468(5):579-87. doi: 10.1007/s00428-016-1905-1. Epub 2016 Jan 29.

PMID:
26832731
9.

MDR-1 and MRP-1 activity in peripheral blood leukocytes of rheumatoid arthritis patients.

Micsik T, Lőrincz A, Gál J, Schwab R, Peták I.

Diagn Pathol. 2015 Dec 30;10:216. doi: 10.1186/s13000-015-0447-1.

10.

The Potential Prognostic Value of Connexin 43 Expression in Head and Neck Squamous Cell Carcinomas.

Dános K, Brauswetter D, Birtalan E, Pató A, Bencsik G, Krenács T, Peták I, Tamás L.

Appl Immunohistochem Mol Morphol. 2016 Aug;24(7):476-81. doi: 10.1097/PAI.0000000000000212.

PMID:
26447893
11.

Evaluation of the good tumor response of embryonal tumor with abundant neuropil and true rosettes (ETANTR).

Mozes P, Hauser P, Hortobágyi T, Benyó G, Peták I, Garami M, Cserháti A, Bartyik K, Bognár L, Nagy Z, Turányi E, Hideghéty K.

J Neurooncol. 2016 Jan;126(1):99-105. doi: 10.1007/s11060-015-1938-3. Epub 2015 Sep 15. Review.

PMID:
26373296
12.

Decreased functional activity of multidrug resistance protein in primary colorectal cancer.

Micsik T, Lőrincz A, Mersich T, Baranyai Z, Besznyák I Jr, Dede K, Zaránd A, Jakab F, Szöllösi LK, Kéri G, Schwab R, Peták I.

Diagn Pathol. 2015 Apr 16;10:26. doi: 10.1186/s13000-015-0264-6.

13.

Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Szokol B, Gyulavári P, Kurkó I, Baska F, Szántai-Kis C, Greff Z, Orfi Z, Peták I, Pénzes K, Torka R, Ullrich A, Orfi L, Vántus T, Kéri G.

ACS Med Chem Lett. 2014 Jan 30;5(4):298-303. doi: 10.1021/ml4003309. eCollection 2014 Apr 10.

14.

[Development and biochemical characterization of EGFR/c-Met dual inhibitors].

Szokol B, Gyulavári P, Baska F, Ibolya K, Greff Z, Szántai KC, Zoltán O, Peták I, Axel U, Vantus T, Kéri G, Orfi L.

Acta Pharm Hung. 2013;83(4):121-33. Hungarian.

PMID:
24575658
15.

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L.

Lung Cancer. 2014 Jan;83(1):109-11. doi: 10.1016/j.lungcan.2013.10.006. Epub 2013 Oct 19.

PMID:
24192513
16.

HeurAA: accurate and fast detection of genetic variations with a novel heuristic amplicon aligner program for next generation sequencing.

Pongor LS, Pintér F, Peták I.

PLoS One. 2013;8(1):e54294. doi: 10.1371/journal.pone.0054294. Epub 2013 Jan 18.

17.

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells.

Dunai ZA, Imre G, Barna G, Korcsmaros T, Petak I, Bauer PI, Mihalik R.

PLoS One. 2012;7(7):e41945. doi: 10.1371/journal.pone.0041945. Epub 2012 Jul 31.

18.

[EGFR tyrosine kinase inhibitors in lung cancer management: sensitivity and resistance].

Moldvay J, Peták I.

Magy Onkol. 2012 Mar;56(1):38-49. doi: MagyOnkol.2012.56.1.38. Epub 2012 Jan 15. Hungarian.

19.

Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.

Árvai K, Nagy K, Barti-Juhász H, Peták I, Krenács T, Micsik T, Végső G, Perner F, Szende B.

Pathol Oncol Res. 2012 Jul;18(3):607-14. doi: 10.1007/s12253-011-9483-7. Epub 2011 Dec 24.

PMID:
22198862
20.

Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone.

Balla P, Moskovszky L, Sapi Z, Forsyth R, Knowles H, Athanasou NA, Szendroi M, Kopper L, Rajnai H, Pinter F, Petak I, Benassi MS, Picci P, Conti A, Krenacs T.

Histopathology. 2011 Sep;59(3):376-89. doi: 10.1111/j.1365-2559.2011.03948.x.

PMID:
22034878

Supplemental Content

Loading ...
Support Center